作者
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, Matteo S Carlino, Nikhil I Khushalani, Fei Ye, Alexander Guminski, Igor Puzanov, Donald P Lawrence, Elizabeth I Buchbinder, Tejaswi Mudigonda, Kristen Spencer, Carolin Bender, Jenny Lee, Howard L Kaufman, Alexander M Menzies, Jessica C Hassel, Janice M Mehnert, Jeffrey A Sosman, Georgina V Long, Joseph I Clark
发表日期
2016/2/1
期刊
JAMA oncology
卷号
2
期号
2
页码范围
234-240
出版商
American Medical Association
简介
Importance
Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known.
Objective
To determine the safety and efficacy of ipilimumab therapy in patients with advanced melanoma with preexisting autoimmune disorders.
Design, Setting, and Participants
Retrospective review of patients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academic tertiary referral centers from January 1, 2012, through August 1, 2015. The data analysis was performed on August 24, 2015.
Exposure
Ipilimumab therapy.
Main Outcomes and Measures
Safety, in terms of frequency of autoimmune flares and conventional immune-related adverse events …
学术搜索中的文章
DB Johnson, RJ Sullivan, PA Ott, MS Carlino… - JAMA oncology, 2016